Farrell 2020.

Study characteristics
Notes	English title Sociodemographic variables as predictors of adverse outcome in SARS‐CoV‐2 infection: an Irish hospital experience Study setting Start of study recruitment (MM/YYYY): 03/2020 End of study recruitment (MM/YYYY): 05/2020 Study design: Prospective cohort Study centre(s): Single centre/clinic/area within a country Number of centres, clinics or areas: 1 Study setting: Inpatient Number of participants recruited: 257 Sampling method: Consecutive participants Participants Female participants (absolute number): 104 Age measure, value: Mean (SD), 60.1 (18.4) Inclusion criteria: NR Exclusion criteria: NR Smoking frequency: 29 Diabetes frequency: NR Hypertension frequency: NR Cardiovascular disease frequency: NR Asthma frequency: NR Chronic obstructive pulmonary disease frequency: NR Other pulmonary disease frequency: NR Immunosuppression frequency: NR Chronic kidney disease frequency: NR Cancer frequency: NR Steroid administration frequency: NR Supplemental oxygen administration frequency: NR Other treatments (frequency): NR Prognostic factor(s) Study’s definition for obesity: Overweight (BMI 25–30) or obese (BMI > 30) The time when obesity has been measured: Before disease or right at presentation Main variable used for determination of obesity: BMI Threshold used for definition: 25 Obesity frequency (absolute number): 166 Prognostic factor(s): Overweight or obese (BMI > 25) Outcome(s) Mortality ICU admission Outcome (prognostic factor) Mortality (overweight or obese (BMI > 25)) Follow‐up Number of patients followed completely for the outcome: 257 Number of obese patients followed completely for the outcome: 166 Number of non‐obese patients followed completely for the outcome: 91 Univariable unadjusted analysis for obesity Effect measure for obesity: NR Effect measure value (95% CI), P value: NR Multivariable analysis for obesity Modelling method: Cox regression The set of prognostic factors used for adjustment: Age, Charlson Comorbidity Index Effect measure for obesity: Hazard ratio Effect measure value (95% CI), P value: 2.20 (0.88, 5.52), 0.093 Outcome (prognostic factor) ICU admission (overweight or obese (BMI > 25)) Follow‐up Number of patients followed completely for the outcome: 257 Number of obese patients followed completely for the outcome: 166 Number of non‐obese patients followed completely for the outcome: 91 Univariable unadjusted analysis for obesity Effect measure for obesity: NR Effect measure value (95% CI), P value: NR Multivariable analysis for obesity Modelling method: Cox regression The set of prognostic factors used for adjustment: Age Effect measure for obesity: Hazard ratio Effect measure value (95% CI), P value: 2.37 (1.37, 6.83), 0.01
Item	Authors' judgement	Support for judgement
Study Participation	Unclear	Appendix 3
Study Attrition Mortality	Unclear	Appendix 3
Study Attrition ICU admission	Unclear	Appendix 3
Prognostic Factor Measurement	Yes	Appendix 3
Outcome Measurement Mortality	Yes	Appendix 3
Outcome Measurement ICU admission	Yes	Appendix 3
Confounding Bias Mortality	No	Appendix 3
Confounding Bias ICU admission	No	Appendix 3
Statistical Analysis Bias	Yes	Appendix 3